Management of Severe Hypertension in Pregnancy

First-Line Treatment Options

The American College of Cardiology and other international guidelines recommend immediate-release oral nifedipine, intravenous labetalol, and intravenous hydralazine as first-line agents for acute severe hypertension in pregnancy, with nifedipine demonstrating superior efficacy compared to other oral agents 1, 2
Immediate-release oral nifedipine should be administered in a dose of 10-20 mg orally, which can be repeated in 20-30 minutes if blood pressure remains severe, with a maximum initial dose of 30 mg total in the first hour 1, 2

Initiate treatment within 60 minutes of the first severe blood pressure reading (≥160 systolic or ≥110 diastolic mmHg) to reduce maternal stroke risk, with the timing starting from the first severe reading, not after confirmation with a second measurement 3
Target blood pressure should be 140-150/90-100 mmHg, avoiding excessive reduction 1, 2

Never administer immediate-release nifedipine concurrently with magnesium sulfate due to the risk of precipitous hypotension and potential maternal/fetal compromise, and use with extreme caution and close blood pressure monitoring if both medications are necessary 2, 4
Administer nifedipine orally only, never sublingually, as sublingual administration increases the risk of sudden, uncontrolled hypotension, and monitor blood pressure closely during the first hour of treatment 2, 5, 6

Nifedipine is particularly advantageous when intravenous access is not available or difficult to establish, rapid treatment is needed in busy or low-resource settings, or the patient has contraindications to beta-blockers, such as asthma or heart block 1

If immediate-release nifedipine is unavailable and IV access is not established, administer 200 mg oral labetalol or 1.0-1.5 g oral methyldopa, although these oral alternatives are less effective than immediate-release nifedipine for acute control 2

No difference exists in maternal hypotension, maternal/fetal outcomes, or adverse effects between nifedipine, labetalol, and hydralazine when used appropriately, with nifedipine not increasing the risk of cesarean section, placental abruption, or fetal compromise when used correctly 2

Expect headache, flushing, dizziness, and peripheral edema with nifedipine use, which are generally mild and do not require treatment discontinuation 4, 5, 6

Concurrent administration of oral nifedipine and magnesium sulfate should be avoided because the combination can cause precipitous hypotension and compromise maternal and fetal circulation. 7

Methyldopa, administered as 250 mg three times daily (titrated up to 4 g/day), is recognized for having the longest safety record among antihypertensive agents used after acute stabilization, although it is associated with a less favorable side‑effect profile compared with other first‑line options. 7